The Supreme Court is set to hear oral arguments in a pivotal case involving the Food and Drug Administration’s (FDA) rejection of two companies’ applications to market flavored e-cigarette liquids. The legal battle stems from the FDA’s decision to deny applications by Triton Distribution and Vapetasia, which a federal appeals court in Louisiana previously overturned, arguing that the FDA had misled these companies during the application process.
The issue has attracted considerable attention due to the conflicting views on the health implications of flavored e-cigarettes. Medical professionals, including the American Medical Association, argue that flavored vapes pose significant health risks to young people, while members of the vaping industry claim that these products aid adults in quitting smoking traditional cigarettes, warning that a ruling detrimental to the companies could severely affect the vaping industry.
This case centers around the Family Smoking Prevention and Tobacco Control Act, enacted in 2009, which requires FDA authorization for new tobacco products. Such approval mandates proof that marketing the product benefits public health. The FDA has classified e-cigarettes as “new tobacco products,” necessitating manufacturer approval to sell them.
The FDA rejected the companies’ applications in 2021, citing the risk to youth associated with flavored e-cigarettes, and noted the absence of evidence showing benefits for adult smokers. The agency’s denial prompted Triton and Vapetasia to seek relief from the U.S. Court of Appeals for the 5th Circuit. Although a three-judge panel initially granted their motion, a full court review ultimately supported the companies, suggesting the FDA had imposed new, unacknowledged requirements.
As the Supreme Court reviews the case, the FDA insists that the 5th Circuit’s role was limited to assessing if the denial was arbitrary and capricious—a standard accepted by other appeals courts, as pointed out by U.S. Solicitor General Elizabeth Prelogar. She argues that the FDA’s denial was based on the insufficient scientific evidence presented, not a lack of studies, and stresses that the FDA did not alter its policies.
Triton and Vapetasia, however, contend that the FDA’s rejection represents arbitrary administrative action, asserting their evidence demonstrates e-cigarettes as a less harmful alternative to traditional tobacco. They claim the FDA altered its requirements without proper notice, hindering their ability to adjust their applications.
Legal professionals and industry observers are keenly watching to see if the court will maintain a narrow focus on whether the FDA’s decision was arbitrary and capricious or if this case will reflect a broader judicial skepticism of agency actions, as highlighted in previous rulings such as Loper Bright Enterprises v. Raimondo.